PLA2G15 is a Lysosomal BMP Hydrolase with Ester Position Specificity and Its Targeting Ameliorates Lysosomal Disease

Kwamina Nyame,Jian Xiong,Arthur de Jong,Hisham N Alsohybe,Matthijs Raaben,Guido Hartmann,Judith A Simcox,Vincent Blomen,Monther Abu-Remaileh

DOI: https://doi.org/10.1101/2024.06.07.597919

2024-06-08

Abstract:Lysosomes catabolize lipids and other biological molecules, a function essential for cellular and organismal homeostasis. Key to lipid catabolism in the lysosome is bis(monoacylglycero)phosphate (BMP), a major lipid constituent of intralysosomal vesicles (ILVs) and a stimulator of lipid-degrading enzymes. BMP levels are altered in a broad spectrum of human conditions, including neurodegenerative diseases. Although BMP synthase was recently discovered, it has long been thought that the unique stereochemistry of BMP confers resistance to acid phospholipases, a requirement for its role in the lysosome. Here, we demonstrate that PLA2G15, a major lysosomal phospholipase, efficiently hydrolyzes BMP with primary esters regardless of stereochemistry. Interestingly, we discover that the unique esterification position of BMP is what confers resistance to hydrolysis. Purified PLA2G15 catabolizes most BMP species derived from cell and tissue lysosomes under acidic conditions. Furthermore, PLA2G15 catalytic activity against synthesized BMP stereoisomers with primary esters was comparable to its canonical substrates. Conversely, BMP with secondary esters is intrinsically stable in vitro and requires acyl migration for hydrolysis in lysosomes. Consistent with our biochemical data, PLA2G15-deficient tissues and cells accumulate multiple BMP species, a phenotype reversible by supplementing wildtype PLA2G15 but not its catalytically dead mutant. Increasing BMP levels by targeting PLA2G15 reverses the cholesterol accumulation phenotype in Niemann Pick Disease Type C (NPC1) patient fibroblasts and significantly ameliorate disease pathologies in NPC1-deficient mice leading to extended lifespan. Our findings establish the rules that govern the stability of BMP in the lysosome and identify PLA2G15 as a lysosomal BMP hydrolase and as a potential target for modulating BMP levels for therapeutic intervention.

Cell Biology

What problem does this paper attempt to address?

The main problem this paper attempts to address is determining the degradation mechanism of bis(monoacylglycerol)phosphate (BMP) in lysosomes, particularly identifying the enzyme responsible for its hydrolysis. It has long been believed that the unique stereochemical structure of BMP provides it with stability in the lysosomal environment, making it resistant to degradation by acidic phospholipases. However, this study challenges that view by experimentally discovering that PLA2G15, a major lysosomal phospholipase, can effectively hydrolyze BMP regardless of its stereochemical configuration. Additionally, the study found that the specific esterification positions of BMP (sn2, sn2') are the key factors protecting it from hydrolysis.

Specifically, the main objectives of the paper include:
1. **Verifying whether BMP can be hydrolyzed by phospholipases in lysosomes**: Researchers demonstrated through experiments that BMP can indeed be hydrolyzed in lysosomes, especially under acidic conditions.
2. **Identifying the enzyme responsible for BMP hydrolysis**: The study found that PLA2G15 is an efficient BMP hydrolase capable of hydrolyzing BMP in lysosomes.
3. **Exploring the stability mechanism of BMP**: The research revealed that the sn2, sn2' esterification positions of BMP are the key factors in its resistance to hydrolysis, rather than its unique stereochemical configuration.
4. **Evaluating the potential therapeutic role of PLA2G15 in diseases**: The study showed that targeting PLA2G15 can increase BMP levels, thereby improving cholesterol accumulation and pathological symptoms in Niemann-Pick disease type C (NPC1) patients, and extending their lifespan.

These findings not only enhance the understanding of BMP metabolism mechanisms but also provide new insights for developing novel therapeutic approaches for lysosome-related diseases.